BiotechTube

Rasagiline

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dementia

Conditions

Dementia, Alzheimer's Disease

Trial Timeline

Aug 1, 2004 → —

NCT ID
NCT00104273

About Rasagiline

Rasagiline is a phase 2 stage product being developed by Eisai for Dementia. The current trial status is completed. This product is registered under clinical trial identifier NCT00104273. Target conditions include Dementia, Alzheimer's Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00104273Phase 2Completed

Competing Products

20 competing products in Dementia

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 3
69
AL001 + Placebo + Open label - AL001AlectorPhase 3
69
AL001AlectorPhase 2
44
ATH-1017 + PlaceboLeonaBioPhase 2
44
IGC AD1 + PlaceboIGC PharmaPhase 1
25
E2020 + PlaceboEisaiApproved
85
ARICEPTEisaiPhase 3
77
Donepezil HydrochlorideEisaiPre-clinical
23
donepezil hclEisaiPhase 3
77
Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placeboEisaiPhase 3
77
E2020 + E2020EisaiPhase 2
52
donepezil hydrochloride (Aricept)EisaiApproved
85
3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + PlaceboEisaiPhase 2
52
E2020 + E2020EisaiPhase 3
77
Irsenontrine + PlaceboEisaiPhase 2
52
E2020EisaiPhase 2
52
MecobalaminEisaiApproved
85
E2020 + PlaceboEisaiPhase 3
77
Donepezil HydrochlorideEisaiPhase 3
77
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved
85

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85